---
document_datetime: 2024-05-14 11:20:06
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/poteligeo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: poteligeo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 4.2324006
conversion_datetime: 2025-12-20 17:15:01.387435
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## POTELIGEO

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IAIN/0024            | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 13/05/2024                          |                                             | SmPC, Annex II, Labelling and PL |           |

1 Notifications  are issued for  type I variations  and Article  61(3) notifications  (unless part of a group including a type II variation  or extension  application  or a worksharing  application).  Opinions are  issued for all  other procedures.

2 A Commission  decision  (CD) is issued for procedures  that affect  the terms of the marketing  authorisation  (e.g.  summary of  product characteristics,  annex  II, labelling,  package  leaflet).  The CD is issued within two  months of  the opinion  for variations  falling  under the scope of  Article  23.1a(a)  of Regulation  (EU) No.  712/2012, or within  one year  for other procedures.

3 SmPC  (Summary  of Product Characteristics),  Annex  II, Labelling,  PL (Package  Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0023             | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                 | 16/01/2024   | n/a        |                                  |                                                                                                                                                                                                                                                                         |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10741 /202303 | Periodic Safety Update EU Single assessment - mogamulizumab                                                                                                                                                                                                                                                                                                | 26/10/2023   | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                       |
| R/0021              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                    | 22/06/2023   | 01/09/2023 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of POTELIGEO in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| II/0020             | B.II.g.2 - Introduction of a post approval change management protocol related to the finished product                                                                                                                                                                                                                                                      | 31/08/2023   | n/a        |                                  |                                                                                                                                                                                                                                                                         |
| II/0019/G           | This was an application for a group of variations. B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range | 26/04/2023   | n/a        |                                  |                                                                                                                                                                                                                                                                         |
| II/0018             | B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS                                                                                                                                                                     | 26/04/2023   | n/a        |                                  |                                                                                                                                                                                                                                                                         |
| PSUSA/10741 /202203 | Periodic Safety Update EU Single assessment - mogamulizumab                                                                                                                                                                                                                                                                                                | 27/10/2022   | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| PSUSA/10741 /202109   | Periodic Safety Update EU Single assessment - mogamulizumab                                                                                                                                                                                                                                                                                                                                                                                                                         | 05/05/2022   | n/a        |                 | PRAC Recommendation -   | maintenance   |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|-------------------------|---------------|
| IA/0016               | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                                                       | 25/04/2022   | 24/04/2023 | SmPC            |                         |               |
| II/0013/G             | This was an application for a group of variations. B.I.a.4.d - Change to in-process tests or limits applied during the manufacture of the AS - Widening of the approved in-process test limits, which may have a significant effect on the overall quality of the AS B.I.a.4.d - Change to in-process tests or limits applied during the manufacture of the AS - Widening of the approved in-process test limits, which may have a significant effect on the overall quality of the | 17/02/2022   | n/a        |                 |                         |               |
| IA/0014               | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                       | 13/12/2021   | 29/04/2022 | Annex II and PL |                         |               |
| PSUSA/10741 /202103   | Periodic Safety Update EU Single assessment - mogamulizumab                                                                                                                                                                                                                                                                                                                                                                                                                         | 28/10/2021   | n/a        |                 | PRAC Recommendation     | - maintenance |
| IB/0011               | B.II.f.1.b.3 - Stability of FP - Extension of the shelf life of the finished product - After dilution or reconstitution (supported by real time data)                                                                                                                                                                                                                                                                                                                               | 23/06/2021   | 29/04/2022 | SmPC and PL     |                         |               |
| PSUSA/10741 /202009   | Periodic Safety Update EU Single assessment - mogamulizumab                                                                                                                                                                                                                                                                                                                                                                                                                         | 06/05/2021   | n/a        |                 | PRAC Recommendation     | - maintenance |

<div style=\"page-break-after: always\"></div>

| II/0008   | B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method   | 14/01/2021   | n/a   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| IB/0007   | B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition                                                                                                                                             | 09/11/2020   | n/a   |

<div style=\"page-break-after: always\"></div>

|                     | of a new in-process test and limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                 |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| PSUSA/10741 /202003 | Periodic Safety Update EU Single assessment - mogamulizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 29/10/2020 | n/a        |                 | PRAC Recommendation - maintenance |
| II/0005/G           | This was an application for a group of variations. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an | 23/07/2020 | n/a        |                 |                                   |
| PSUSA/10741 /201909 | Periodic Safety Update EU Single assessment - mogamulizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 17/04/2020 | n/a        |                 | PRAC Recommendation - maintenance |
| IAIN/0003/G         | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name                                                                                                                                                                                                         | 06/11/2019 | 19/10/2020 | Annex II and PL |                                   |

<div style=\"page-break-after: always\"></div>

|                     | and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing   |            |     |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10741 /201903 | Periodic Safety Update EU Single assessment - mogamulizumab                                                                                                                                                                                                                                                                                                                                                                                                                               | 31/10/2019 | n/a | PRAC Recommendation - maintenance |
| IB/0002             | B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                               | 26/07/2019 | n/a |                                   |